Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.54 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163023 | 1.00 | MAPK1 (0.59) | MAPK1OPRK1CHEK1CDK2AP1HDAC4 | |
| SCHEMBL28280152 | 1.00 | MAPK1 (0.59) | MAPK1OPRK1CHEK1CDK2AP1HDAC4 | |
| SCHEMBL7865237 | 0.95 | CHEK1 (0.55) | MAPK1OPRK1CHEK1CDK2AP1HDAC4 | |
| Trifluoroacetic Acid SCHEMBL4259150 | 0.92 | HDAC4 (0.56) | MAPK1OPRK1CHEK1CDK2AP1HDAC4 | |
| Cadaverine Tartrate SCHEMBL28008723 | 0.92 | MAPK1 (0.52) | MAPK1OPRK1CHEK1CDK2AP1HDAC4 | |
| SCHEMBL8491815 | 0.90 | MEN1 (0.54) | MAPK1OPRK1HDAC4NPC1RAB9A | |
| SCHEMBL1250846 | 0.90 | MEN1 (0.54) | MAPK1OPRK1HDAC4NPC1RAB9A | |
| SCHEMBL5230051 | 0.90 | MEN1 (0.54) | MAPK1OPRK1HDAC4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL994487 | 0.89 | MEN1 (0.53) | MAPK1OPRK1HDAC4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL28156652 | 0.89 | MEN1 (0.53) | MAPK1OPRK1HDAC4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-109476633-A | The inhibitor of tryptophan 2,3- dioxygenase | 荷兰转化研究中心有限责任公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-104387315-A | Compound I and (R)-3-aminopiperidine hydrochloride II, preparation method and application in Linagliptin synthesis | 2Y CHEM LTD | 2015-03-04 | — | — | CN | disclosed |
| EP-2125819-B1 | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases | BRISTOL MYERS SQUIBB CO (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2789615-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| CN-103373953-A | Preparation method for 3-aminopiperidine and optical isomer thereof | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2013-10-30 | — | — | CN | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| EP-2125819-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116064-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088791-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM5, CHRM2 | MAPK1 1034/4885OPRK1 290/4885CHEK1 2392/4885 |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | MAPK1 205/4885OPRK1 1343/4885CHEK1 151/4885 |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | MAPK1 127/4885OPRK1 2521/4885CHEK1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.